MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Clinical trial NCT06549751 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06549751
- Sponsor
- Marker Therapeutics, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-16
- Primary completion
- 2028-07-16
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.